[ad_1]
The prescription drug Koronavir was approved after another drug developed in Russia, Avifavir, was approved in May. Both drugs are based on the Japanese active ingredient favipiravir, which is widely used in the country. This drug is used in Japan to treat various viral diseases.
R-Pharm’s announcement is another sign that Russia is seeking to lead the COVID-19 drug race, in which the entire world is involved. The country exports its developed COVID-19 tests and has concluded several transactions for the supply of the Russian Sputnik-V vaccine.
The company that developed Koronavir has announced that the drug has been approved in a Level 3 clinical trial involving 168 patients.
Clinical trials in Russia have been very small in scale. On Friday, the European Health Regulatory Authority approved the use of the steroid drug dexamethasone in the COVID-19 disease after researchers in the United Kingdom (United Kingdom) tested the drug’s effectiveness with several thousand people.
The active substance, favipiravir, is also used in Avigan, a medicine manufactured by Fujifilm Holdings Corp. in 2014. It has been approved in Japan as an emergency medicine for the treatment of influenza virus disease. There are worldwide studies to test the efficacy of favipiravir in COVID-19. The results of a study conducted in Japan in July were insufficient to consider the drug effective.
No part of this publication may be reproduced without the written permission of ELTA.
[ad_2]
